Lannett Co (Lannett Co) ROCE % : 0.00% (As of Mar. 2023)

View and export this data going back to 1994. Start your Free Trial

What is Lannett Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Lannett Co's annualized ROCE % for the quarter that ended in Mar. 2023 was 0.00%.

Lannett Co ROCE % Historical Data

The historical data trend for Lannett Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lannett Co ROCE % Chart

Lannett Co Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

ROCE %

Get a 7-Day Free Trial

9.82

-21.94

1.89

-32.87

-36.17

Lannett Co Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
ROCE %	Get a 7-Day Free Trial															-17.69	-72.77	-14.07	-24.69	-

Lannett Co ROCE % Calculation

Lannett Co's annualized ROCE % for the fiscal year that ended in Jun. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2022 )		(A: Jun. 2021 )		(A: Jun. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2022 )		(A: Jun. 2021 )		(A: Jun. 2022 )
	=	-175.945	/	( ( (683.737 - 90.469)	+	(484.435 - 104.94) )	/ 2 )
	=	-175.945	/	( (593.268	+	379.495)	/ 2 )
	=	-175.945	/	486.3815
	=	-36.17 %

Lannett Co's ROCE % of for the quarter that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2023 )		(Q: Dec. 2022 )		(Q: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2023 )		(Q: Dec. 2022 )		(Q: Mar. 2023 )
	=	-345.048	/	( ( (438.359 - 112.216)	+	(334.624 - 733.079) )	/ 2 )
	=	-345.048	/	( ( 326.143	+	-398.455 )	/ 2 )
	=	-345.048	/	-36.156
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2023) EBIT data.

Lannett Co (OTCPK:LCINQ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Lannett Co ROCE % Related Terms

Thank you for viewing the detailed overview of Lannett Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lannett Co (Lannett Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lannett Co Inc (OTCPK:LCINQ) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1150 Northbrook Drive, Suite 155, Trevose, PA, USA, 19053

Website

https://www.lannett.com

Lannett Co Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products. It offers solid oral, extended-release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. In addition, the company also provides its products for various medical indications comprising glaucoma, gastrointestinal, migraine, obesity, respiratory, and others. It operates in the segment of generic pharmaceuticals. Its customers include generic pharmaceutical distributors, drug wholesalers, chain drug stores, private label distributors, mail-order pharmacies, and others.

Executives

John C Chapman	director	9000 STATE ROAD, PHILADELPHIA PA 19136
Timothy C Crew	officer: Chief Executive Officer	9000 STATE ROAD, PHILADELPHIA PA 19136
Patrick G Lepore	director	17-17 ROUTE 208 N, FAIRLAWN NJ 07410
Melissa Rewolinski	director	9000 STATE ROAD, PHILADELPHIA PA 19136
Jeffrey Farber	officer: Secretary
Samuel H Israel	officer: Chief Legal Officer	9000 STATE ROAD, PHILADELPHIA PA 19136
John Abt	officer: Vice President of Quality	9000 STATE ROAD, PHILADELPHIA PA 19136
John Kozlowski	officer: Chief Operating Officer	9000 STATE ROAD, PHILADELPHIA PA 19136
David A Drabik	director	9000 STATE RD, PHILADELPHIA PA 19136
Paul Taveira	director	9000 STATE ROAD, PHILADELPHIA PA 19136
Albert Iii Paonessa	director	9852 NW 2ND COURT, PLANTATION FL 33324
Kevin Smith	other: Vice President
Maureen Cavanaugh	officer: Senior Vice President and CCOO	9000 STATE ROAD, PHILADELPHIA PA 19136
David Farber	officer: Treasurer
Arthur P Bedrosian	officer: President	P O BOX D 1400, POMONA NY 10970